Scarica l'app Stockscreener
3.98
3.38%
0.13
Dopo l'orario di chiusura:
4.06
0.08
+2.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Iovance Biotherapeutics Stock Short Interest Falls to 32.69% - Quiver Quantitative
IOVA Stock Rises As Rival’s FDA Setback Lifts Amtagvi - StocksToTrade
IOVA Stock Draws Bullish Calls As Rival Stumbles On FDA Setback - timothysykes.com
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com
CM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics | ARS: Annual Report to Security Holders - Moomoo
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - AOL.com
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - The Motley Fool
IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN
Iovance’s Plan to Lift Authorized Shares to 650 Million Could Be A Game Changer For Iovance Biotherapeutics (IOVA) - Sahm
[ARS] IOVANCE BIOTHERAPEUTICS, INC. SEC Filing - Stock Titan
MSN Money - MSN
IOVA Earnings History & Surprises | EPS & Revenue Results | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics senior executive joins cancer research panel to promote flexible innovation in immunotherapy - Traders Union
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Iovance Biotherapeutics (IOVA) to Post Earnings on Thursday - MarketBeat
Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding - Yahoo Finance
Iovance Biotherapeutics | DEFA14A: Others - Moomoo
Iovance Biotherapeutics | DEF 14A: Definitive information statements - Moomoo
Iovance (NASDAQ: IOVA) seeks approval to raise authorized common shares to 650M - Stock Titan
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out (NASDAQ:IOVA) - Seeking Alpha
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery And Undervalued Narrative - Sahm
IOVA shares jump 8% — what’s retail expecting? - MSN
May 7 at 8:30 ET: Iovance to give Q1 results and updates - Stock Titan
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 - Yahoo Finance
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Iovance Biotherapeutics (IOVA) down 2.1% since last earnings report: Can it rebound? - MSN
Chardan Capital Maintains Iovance Biotherapeutics (IOVA) Buy Recommendation - MSN
Iovance falls after guidance cut, revenue miss - MSN
Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative? - Sahm
IOVA Forecast, Price Target & Analyst Ratings | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4%Here's What Happened - MarketBeat
IOVA Stock Grinds Lower As Traders Watch Key Support - StocksToTrade
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug - Insider Monkey
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Iovance Biotherapeutics (IOVA) - The Globe and Mail
Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA) - Insider Monkey
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics (NASDAQ: IOVA) seeks votes on ESPP + share increase - Stock Titan
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? - Yahoo Finance
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Three Month Share Price Surge - Sahm
Chardan Capital Lowers Price Target for IOVA, Maintains Buy Rati - GuruFocus
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):